Antiallergy Drugs as Potent Inhibitors of Lipase with Structure-activity Relationships and Molecular Docking

Author(s): Benarous Khedidja*, Benguechoua Madjda, Ghibeche Abderrahmane

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 17 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Inhibition activity of 8 synthetic molecules known as anti-allergy drugs on lipases has been investigated. The enzymatic inhibition produced by these molecules is described here for the first time.

Objective: The used anti-allergy drugs are: Loratidine, primalan, zyrtec, histagan, periactin, ketotifene, rifex and bilastine.

Methods: Lipase inhibition is studied using the spectrophotometric method. Molecular docking has been achieved for the first time for these drugs using AutoDock Vina program to discuss the nature of interactions, structure-activity relationship and the mechanism of inhibition.

Results: The biological evaluation of these molecules showed that most of these drugs are potent lipase inhibitors with competitive type inhibition. The best drug is loratidine with IC50=0.44mg/ml and Ki=0.86 mM and competitive type inhibition. Molecular docking studies of the studied molecules confirmed their competitive inhibitory type with their binding to the Catalytic Active Site (CAS) of lipases.

Conclusion: Hence, these drugs could be used for obesity or candidiasis treatment taking advantage of the much-known details of their secondary effects as antiallergy drugs.

Keywords: Autodock vina, lipase inhibition, loratidine, molecular docking, synthetic anti-allergy drugs, Candida rugosa.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 10 September, 2018
Page: [95 - 101]
Pages: 7
DOI: 10.2174/1871523017666180910120150

Article Metrics

PDF: 35